Review and analysis of FDA approved drugs using lipid-based formulations

References

• Dahan A, Hoffman A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release. 2008;129:1–10.
   PubMed Web of Science ®Google Scholar
• Crew M. Bioavailability enhancement - analysis of the Historical Use of Solubilization Technologies. Drug Development & Delivery. 2014. Available from: http://www.drug-dev.com/Main/Back-Issues/BIOAVAILABILITY-ENHANCEMENT-Analysis-of-the-Histor-657.aspx#sthash.xOZ5heIQ.dpuf
   Google Scholar
• Feeney OM, Crum MF, McEvoy CL, et al. 50years of oral lipid-based formulations: Provenance, progress and future perspectives. Adv Drug Deliv Rev. 2016;101:167–194.
   PubMed Web of Science ®Google Scholar
• Strickley RG. Currently marketed oral lipid-based dosage forms: drug products and excipients. In: Hauss D, editor. Oral lipid based formulations. 1st ed. New York: Informa Healthcare; 2007.
   Google Scholar
• Wishart DS, Knox C, Guo AC, et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34:D668–D672.
   PubMed Web of Science ®Google Scholar
• Strickley RG. Solubilizing excipients in oral and injectable formulations. Pharm Res. 2004;21:201–230.
   PubMed Web of Science ®Google Scholar
• Agrawal SGT, Tripathi DK, Alexander A. A review on novel therapeutic strategies for the enhancement of solubility for hydrophobic drugs through lipid and surfactant based self micro emulsifying drug delivery system: a novel approach. Am J Drug Discov Dev. 2012;2:143–183.
   Google Scholar
• Porter CJH. Oral lipid-based formulations: Using pre-clinical data to dictate formulation strategies for poorly water soluble drugs. In: Hauss D, editor. Oral lipid-based formulations: enhancing the bioavailability of poorly water-soluble drugs. New York Informa Healthcare; 2007. p. 185–205.
   Google Scholar
• Gullapalli RP. Soft gelatin capsules (softgels). J Pharm Sci. 2010;99:4107–4148.
   PubMed Web of Science ®Google Scholar
• Jones WJ, 3rd, Francis JJ. Softgels: consumer perceptions and market impact relative to other oral dosage forms. Adv Ther. 2000;17:213–221.
   PubMed Web of Science ®Google Scholar
• Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006;29:278–287.
   PubMed Web of Science ®Google Scholar
• Griffin B. Advances in lipid-based formulations: overcoming the challenge of low bioavailability for poorly water soluble drug compounds. Am Pharm Rev. March 2012. Available from: http://www.americanpharmaceuticalreview.com/Featured-Articles/39299-Advances-in-Lipid-based-Formulations-Overcoming-the-Challenge-of-Low-Bioavailability-for-Poorly-Water-Soluble-Drug-Compounds/
   Google Scholar
• MacGregor KJ, Embleton JK, Lacy JE, et al. Influence of lipolysis on drug absorption from the gastro-intestinal tract. Adv Drug Deliv Rev. 1997;25:33–46.
   Web of Science ®Google Scholar
• Kahan BD, Dunn J, Fitts C, et al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals. Transplantation 1995;59:505–511.
   PubMed Web of Science ®Google Scholar
• Mendez R, Abboud H, Burdick J, et al. Reduced intrapatient variability of cyclosporine pharmacokinetics in renal transplant recipients switched from oral sandimmune to neoral. Clin. Ther.. 1999;21:160–171.
   PubMed Web of Science ®Google Scholar
• Katneni K, Charman SA, Porter CJ. Impact of cremophor-EL and polysorbate-80 on digoxin permeability across rat jejunum: delineation of thermodynamic and transporter related events using the reciprocal permeability approach. J Pharm Sci. 2007;96:280–293.
   PubMed Web of Science ®Google Scholar
• Wacher VJ, Silverman JA, Zhang Y, et al. Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci. 1998;87:1322–1330.
   PubMed Web of Science ®Google Scholar
• Kim AE, Dintaman JM, Waddell DS, et al. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther. 1998;286:1439–1445.
   PubMed Web of Science ®Google Scholar
• Schmitt C, Kaeser B, Riek M, et al. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe. CP. 2010;48:192–199.
   Google Scholar
• Perloff MD, Von Moltke LL, Marchand JE, et al. Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. J Pharm Sci. 2001;90:1829–1837.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Gudmundsson OS, Hageman MJ. Application of lipid-based formulations in drug discovery. J Med Chem. 2012;55:7945–7956.
   PubMed Web of Science ®Google Scholar
• Gao P. MW. Case studies: development of self-emulsifying formulations for improving the oral bioavailability of poorly soluble, lipophilic drugs. In: DJ H, editor. Oral lipid-based formulations enhancing the bioavailability of poorly water soluble drugs. 1st ed. New York: Informa Healthcare; 2007.
   Google Scholar
• Pouton CW, Porter CJ. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008;60:625–637.
   PubMed Web of Science ®Google Scholar
• Backman TW, Cao Y, Girke T. ChemMine tools: an online service for analyzing and clustering small molecules. Nucleic Acids Res. 2011;39:W486–W491.
   PubMed Web of Science ®Google Scholar
• Constantinides PP, Wasan KM. Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. J Pharm Sci. 2007;96:235–248.
   PubMed Web of Science ®Google Scholar
• Aungst BJ. Absorption enhancers: applications and advances. AAPS J. 2012;14:10–18.
   PubMed Web of Science ®Google Scholar
• Akhtar N, Ahad A, Khar RK, et al. The emerging role of P-glycoprotein inhibitors in drug delivery: a patent review. Expert Opin Ther Pat. 2011;21:561–576.
   PubMed Web of Science ®Google Scholar
• Kayser O, Olbrich C, Yardley V, et al. Formulation of amphotericin B as nanosuspension for oral administration. Int J Pharm. 2003;254:73–75.
   PubMed Web of Science ®Google Scholar
• Lindmark T, Kimura Y, Artursson P. Absorption enhancement through intracellular regulation of tight junction permeability by medium chain fatty acids in Caco-2 cells. J Pharmacol Exp Ther. 1998;284:362–369.
   PubMed Web of Science ®Google Scholar
• Veber DF, Johnson SR, Cheng HY, et al. Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 2002;45:2615–2623.
   PubMed Web of Science ®Google Scholar
• Hou TJ, Zhang W, Xia K, et al. ADME evaluation in drug discovery. 5. Correlation of Caco-2 permeation with simple molecular properties. J Chem Inf Comput Sci. 2004;44:1585–1600.
   PubMedGoogle Scholar
• Flaten GE, Luthman K, Vasskog T, et al. Drug permeability across a phospholipid vesicle-based barrier 4. The effect of tensides, co-solvents and pH changes on barrier integrity and on drug permeability. Eur J Pharm Sci. 2008;34:173–180.
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley JF, Saivin S, et al. Effect of polyoxyl 35 castor oil and Polysorbate 80 on the intestinal absorption of digoxin in vitro. Arzneimittelforschung 2000;50:576–579.
   PubMed Web of Science ®Google Scholar
• Mullertz A, Ogbonna A, Ren S, et al. New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. J Pharm Pharmacol. 2010;62:1622–1636.
   PubMed Web of Science ®Google Scholar
• Leeson PD, Springthorpe B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat Rev Drug Discov. 2007;6:881–890.
   PubMed Web of Science ®Google Scholar
• Adkins JC, Faulds D. Amprenavir. Drugs 1998;55:837–842. discussion 43-4.
   PubMed Web of Science ®Google Scholar
• Amidon GL, Lennernas H, Shah VP, et al. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res. 1995;12:413–420.
   PubMed Web of Science ®Google Scholar
• Butler JM, Dressman JB. The developability classification system: application of biopharmaceutics concepts to formulation development. J Pharm Sci. 2010;99:4940–4954.
   PubMed Web of Science ®Google Scholar
• Dahan A, Hoffman A. The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm. 2007;67:96–105.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Kaukonen AM, Taillardat-Bertschinger A, et al. Use of in vitro lipid digestion data to explain the in vivo performance of triglyceride-based oral lipid formulations of poorly water-soluble drugs: studies with halofantrine. J Pharm Sci. 2004;93:1110–1121.
   PubMed Web of Science ®Google Scholar
• Lipinski CA, Lombardo F, Dominy BW, et al. approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46:3–26.
   PubMed Web of Science ®Google Scholar
• Bergstrom CA, Charman WN, Porter CJ. Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Adv Drug Deliv Rev. 2016;101:6–21.
   PubMed Web of Science ®Google Scholar
• Leeson PD. Molecular inflation, attrition and the rule of five. Adv Drug Deliv Rev. 2016;101:22–33.
   PubMed Web of Science ®Google Scholar
• Fleisher D, Li C, Zhou Y, et al. Drug, meal and formulation interactions influencing drug absorption after oral administration. Clin Pharmacokinet. 1999;36:233–254.
   PubMed Web of Science ®Google Scholar
• Gu CH, Li H, Levons J, et al. Predicting effect of food on extent of drug absorption based on physicochemical properties. Pharm Res. 2007;24:1118–1130.
   PubMed Web of Science ®Google Scholar
• Rao S, Tan A, Thomas N, et al. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. J Control Release. 2014;193:174–187.
   PubMed Web of Science ®Google Scholar
• Martins S, Sarmento B, Ferreira DC, et al. Lipid-based colloidal carriers for peptide and protein delivery – liposomes versus lipid nanoparticles. Int J Nanomed. 2007;2:595–607.
   PubMed Web of Science ®Google Scholar
• Hintzen F, Perera G, Hauptstein S, et al. In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin. Int J Pharm. 2014;472:20–26.
   PubMed Web of Science ®Google Scholar
• Liu D, Kobayashi T, Russo S, et al. In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery. AAPS J. 2013;15:288–298.
   PubMed Web of Science ®Google Scholar
• Guo L, Ma E, Zhao H, et al. Preliminary evaluation of a novel oral delivery system for rhPTH1-34: in vitro and in vivo. Int J Pharm. 2011;420:172–179.
   PubMed Web of Science ®Google Scholar
• Ratain MJ. Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011;29:3958–3959.
   PubMed Web of Science ®Google Scholar
• Kang SP, Ratain MJ. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010;16:4446–4451.
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Drug Watch. [cited 2016 Nov 4]. Available at: https://www.drugwatch.com/2012/01/18/fda-black-box-warnings/
   Google Scholar
• Cerpnjak K, Zvonar A, Gasperlin M, et al. Lipid-based systems as a promising approach for enhancing the bioavailability of poorly water-soluble drugs. Acta Pharmaceutica (Zagreb, Croatia) 2013;63:427–445.
   PubMed Web of Science ®Google Scholar
• Yalkowsky SH. Handbook of Aqueous Solubility Data: An Extensive Compilation of Aqueous Solubility Data for Organic Compounds Extracted from the AQUASOL dATAbASE. Boca Raton, Florida: CRC Press LLC; 2003. p. 1263.
   Google Scholar
• Food and Drug Administration. Drugs. [cited 2016 Nov 4]. Available from: http://www.fda.gov/Drugs/default.htm
   Google Scholar
• Abelcet^® [package insert]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals Inc; 2013.
   Google Scholar
• Janoff AS, Boni LT, Popescu MC, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA. 1988;85:6122–6126.
   PubMed Web of Science ®Google Scholar
• Mistro S, Maciel Ide M, de Menezes RG, et al. Does lipid emulsion reduce amphotericin B nephrotoxicity? A systematic review and meta-analysis. Clin Infect Dis. 2012;54:1774–1777.
   PubMed Web of Science ®Google Scholar
• Guo LS. Amphotericin B colloidal dispersion: an improved antifungal therapy. Adv Drug Deliv Rev. 2001;47:149–163.
   PubMed Web of Science ®Google Scholar
• Johansen HK, Gotzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2014;(9):CD000969.
   PubMed Web of Science ®Google Scholar
• Chen Y-C, Su C-Y, Jhan H-J, et al. Physical characterization and in vivo pharmacokinetic study of self-assembling amphotericin B-loaded lecithin-based mixed polymeric micelles. Int J Nanomed. 2015;10:7265–7274.
   PubMed Web of Science ®Google Scholar
• Porter CJ, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007;6:231–248.
   PubMed Web of Science ®Google Scholar
• Trevaskis NL, Charman WN, Porter CJ. Lipid-based delivery systems and intestinal lymphatic drug transport: a mechanistic update. Adv Drug Deliv Rev. 2008;60:702–716.
   PubMed Web of Science ®Google Scholar
• Yanez JA, Wang SW, Knemeyer IW, et al. Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011;63:923–942.
   PubMed Web of Science ®Google Scholar
• Zgair A, Wong JC, Lee JB, et al. Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines. Am J Trans Res. 2016;8:3448–3459.
   PubMed Web of Science ®Google Scholar
• Sachs-Barrable K, Lee SD, Wasan EK, et al. Enhancing drug absorption using lipids: a case study presenting the development and pharmacological evaluation of a novel lipid-based oral amphotericin B formulation for the treatment of systemic fungal infections. Adv Drug Deliv Rev. 2008;60:692–701.
   PubMed Web of Science ®Google Scholar
• Risovic V, Boyd M, Choo E, et al. Effects of lipid-based oral formulations on plasma and tissue amphotericin B concentrations and renal toxicity in male rats. Antimicrob Agents Chemother. 2003;47:3339–3342.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Wasan EK, Lin M, et al. Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. J Antimicrob Chemother. 2009;64:101–108.
   PubMed Web of Science ®Google Scholar
• Sivak O, Gershkovich P, Lin M, et al. Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model. Lipids Health Dis. 2011;10:135. Epub 2011/08/10.
   PubMed Web of Science ®Google Scholar
• Risovic V, Rosland M, Sivak O, et al. Assessing the antifungal activity of a new oral lipid-based amphotericin B formulation following administration to rats infected with Aspergillus fumigatus. Drug Dev Ind Pharm. 2007;33:703–707.
   PubMed Web of Science ®Google Scholar
• Gershkovich P, Wasan EK, Sivak O, et al. Visceral leishmaniasis affects liver and spleen concentrations of amphotericin B following administration to mice. J Antimicrob Chemother. 2010;65:535–537.
   PubMed Web of Science ®Google Scholar
• Wasan EK, Gershkovich P, Zhao J, et al. A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model. PLoS Negl Trop Dis. 2010;4:e913.
   PubMed Web of Science ®Google Scholar
• Perlin DS. Amphotericin B cochleates: a vehicle for oral delivery. Curr Opin Investig Drugs. 2004;5:198–201.
   PubMedGoogle Scholar
• Sesana AM, Monti-Rocha R, Vinhas SA, et al. In vitro activity of amphotericin B cochleates against Leishmania chagasi. Mem Inst Oswaldo Cruz. 2011;106:251–253.
   PubMed Web of Science ®Google Scholar
• Lemke A, Kiderlen AF, Kayser O. Amphotericin B. Appl Microbiol Biotechnol. 2005;68:151–162.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Jaiswal AK, Asthana S, et al. Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy. Br J Pharmacol. 2015;172:3596–3610.
   PubMed Web of Science ®Google Scholar
• Yang Z, Chen M, Yang M, et al. Evaluating the potential of cubosomal nanoparticles for oral delivery of amphotericin B in treating fungal infection. Int J Nanomed. 2014;9:327–336.
   PubMed Web of Science ®Google Scholar
• Yang Z, Tan Y, Chen M, et al. Development of amphotericin B-loaded cubosomes through the SolEmuls technology for enhancing the oral bioavailability. AAPS PharmSciTech. 2012;13:1483–1491.
   PubMed Web of Science ®Google Scholar
• Delmas G, Park S, Chen ZW, et al. Efficacy of orally delivered cochleates containing amphotericin B in a murine model of Aspergillosis. Antimicrob Agents Chemother. 2002;46:2704–2707.
   PubMed Web of Science ®Google Scholar